Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ubrogepant for the Preventive Treatment of Menstrual Migraine
NCT06417775Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Sep 2024
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of ubrogepant in menstrual migraine (3 arms), sponsored by AbbVie Inc. Primary endpoints: Change From Baseline in Number of Migraine Days Occurring During Perimenstrual Periods (PMPs) at 16 weeks and Number of Participants With Adverse Events (AEs) at 68 weeks. Started Sep 2024; status: active, not recruiting.
02
Drugs
ubrogepant
03
Conditions
menstrual migraine
Beyond the preview
Go deeper on NCT06417775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06417775.